ABPI Logo
  • What we do
    • Working with Government and Parliament
    • Working with the NHS
    • Working with Industry and academia
    • Working with charities and patient organisations
    • Supporting medicines and vaccines development
    • How medicines are priced in the UK
    • Global campaigns
    FEATURED
    Brexit

    The ABPI is at the heart of a health sector-wide effort to establish consensus on key Brexit issues. Click here for our view and for more information about how our sector is preparing for Brexit if there's 'no deal'.

    FEATURED
    Devolved Nations How medicines are priced in the UK

    Medicines bring huge value to NHS patients. The development of new medicines is uncertain, costly, and involves significant rates of failure. Find out how pharmaceutical companies are pioneering R&D into the next generation of treatments. 

  • Ethics
    • Disclosure UK
    • Clinical trial transparency
    • Research using animals
    FEATURED
    Disclosure UK

    The relationship between the pharmaceutical industry and healthcare professionals (HCPs) and healthcare organisations (HCOs) plays a vital role in the development and delivery of life-enhancing and life-saving medicines. 

    FEATURED
    Hospital Clinical trial transparency

    Clinical trials are the cornerstone of the research and development process and it is through trials that pharmaceutical companies are able to demonstrate the safety and efficacy of new medicines.

  • Facts and Figures
    • UK pharmaceutical market
    • Global pharmaceutical market
    • Science and innovation
    • Industry and academia
    FEATURED
    Science and innovation

    Medicines and vaccines have helped deliver incredible improvements in patient health. This section looks at expenditure on R&D in the UK and around the world.

    FEATURED
    Industry and academia

    The UK is a world leader in medical research and innovation, built on the foundation of collaborations between industry and academia throughout Britain.

  • Membership and events
    • Events
    • Working with our members​
    • ABPI Members List
    • Membership FAQs
    • Full membership
    • General Affiliate membership
    • Research Affiliate membership
    FEATURED
    Events

    Discover events for both members and non-members as well as speaking engagements of senior ABPI leadership.

     

    FEATURED
    Working with our members Working with our members​

    As a membership organisation we work with our member companies, and the expertise of the specialists they employ, to develop and present our points of view to UK and European governments, the public and to other stakeholders.

  • Who We Are
  • Media
  • Publications
  • Careers
  • Contact Us
MY ABPI LOGIN
  • The Association of the British Pharmaceutical Industry
  • Media Centre
  • Blog
  • Fighting AMR by stopping infections before they start

Fighting AMR by stopping infections before they start

12 Feb 2019 Posted in Opinion By Darius Hughes, Head of Vaccines at Pfizer UK

Preventing infections will help us get antimicrobial resistance (AMR) under control, according to a new plan from the UK Government.

Increasing the use of vaccines to prevent people from catching infections in the first place could help the UK reduce the number of antibiotics it uses and start turning the tide in the fight against AMR.

These are just some of the proposals in the Government’s new action plan for AMR, which looks at the different ways the UK will be taking a leading role in this global health issue.

Every year there are ~700,000 deaths globally from drug-resistant infections1. If left unchecked, this could increase to an estimated 10 million deaths per year by 20502

Vaccines already play a really important role in stopping people catching infections and reducing the spread of infection. We want this role to grow.

Research has shown that the flu vaccine can reduce the use of antibiotics by as much as 64% in vaccinated individuals.3

England has one of the best immunisation programmes in the world, despite spending only around 0.4% of its health budget on vaccines4.

This is a great foundation for us to build on. When the UK is deciding which new vaccines to give to the public, it will be important for them to think about how those vaccines can help reduce AMR.

While there are many vaccines programmes in the UK in place to protect children and adults from serious infections, not everyone chooses to follow them.

Looking at ways to make sure people are vaccinated against infections is important.

The good news is that pharmaceutical companies are researching and developing new vaccines, including those which target some of today’s most challenging drug resistant infections.

We’re also working hard to make sure people understand the importance of vaccination in keeping people healthy.

We need to make the most of these new vaccines once they’re ready to start being used, and make sure we prioritise preventing infections as well as treating them.

References
  1. Tackling Drug-Resistant Infections Globally, The Review on Antimicrobial Resistance, Chaired by Jim O’Neill and published by the Wellcome Trust and HM Government, 2016https://amr-review.org/sites/default/files/160518_Final%20paper_with%20cover.pdf
  2. Antimicrobial Resistance: Tackling a Crisis for the Health and Wealth of Nations, The Review on Antimicrobial Resistance, Chaired by Jim O’Neill and published by the Wellcome Trust and HM Government, 2014 https://amr-review.org/sites/default/files/AMR%20Review%20Paper%20-%20Tackling%20a%20crisis%20for%20the%20health%20and%20wealth%20of%20nations_1.pdf
  3. Vaccines Europe: The role of vaccination in reducing antimicrobial resistance (AMR) https://www.vaccineseurope.eu/wp-content/uploads/2013/09/AMR-and-Vaccines-June-2013.pdf
  4. Human Vaccines and Immunotherapeutic: How much money is spent on vaccines across Western European countries? Aug 2016 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4994728/ 

Blog

The good news is that pharmaceutical companies are researching and developing new vaccines, including those which target some of today’s most challenging drug resistant infections.

Darius Hughes, Head of Vaccines at Pfizer UK

RELATED LINKS

  • Antimicrobial resistance (AMR)
  • UK launches national plan to tackle AMR

ABPI

The Association of the British Pharmaceutical Industry is a company limited by guarantee registered in England and Wales 
(registered number 09826787) and its registered office is at 7th Floor Southside,105 Victoria Street, London, SW1E 6QT.
Telephone +44 (0) 207 9303477

© ABPI 2019

Devolved Nations

  • Cymru Wales
  • Northern Ireland
  • Scotland

Quick Links

  • ABPI Exam
  • Careers
  • Disclosure UK
  • Job Opportunities
  • Schools

Website Info

  • Terms and conditions
  • Accessibility
  • Cookie Policy
  • Privacy Policy
  • Twitter Logo
  • LinkedIn
  • YouTube Logo

Prescription Medicines Code of Practice Authority (PMCPA)

The Prescription Medicines Code of Practice Authority (PMCPA) was established by The Association of the British Pharmaceutical Industry to operate the ABPI Code of Practice for the Pharmaceutical Industry independently of the ABPI. The PMCPA is a division of ABPI which is a company registered in England and Wales (registered number 09826787) with its registered office at 7th Floor, Southside, 105 Victoria Street, London SW1E 6QT.

Office of Health Economics (OHE)

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 7th Floor Southside, 105 Victoria Street, London, SW1E 6QT. OHE provides independent research, advisory and consultancy services on policy implications and economic issues within the pharmaceutical, health care and biotechnology sectors.